Optimization of MrgX1 allosteric agonists as potential therapies for chronic pain

MrgX1 变构激动剂的优化作为慢性疼痛的潜在疗法

基本信息

  • 批准号:
    10112868
  • 负责人:
  • 金额:
    $ 39.25万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-09-15 至 2023-02-28
  • 项目状态:
    已结题

项目摘要

Chronic pain is a major health and economic problem worldwide. Because the major analgesics (e.g., opioids) bind to receptors that are widely expressed throughout the central nervous system (CNS), dose-limiting adverse effects and significant risk of addiction and abuse present substantial barriers to their clinical use. Pain sensing neurons (a.k.a nociceptors) in dorsal root ganglion (DRG) play essential role in pain transmission by detecting painful signals in the periphery such as skin and viscera. Therefore, targeting molecules specifically expressed in nociceptors may offer an opportunity for pain-selective pharmacologic interventions. Our previous data have shown that Mrgs including mouse MrgC11 and human MrgX1 are specifically expressed in nociceptors in DRG and constitute an endogenous anti-pain pathway. Funded R03 grant allowed us to identify selective and potent MrgX1 allosteric agonists. Preliminary data showed that two allosteric agonists inhibited persistent pain in humanized MrgX1 mice. MrgX1 allosteric agonists may potentially become novel anti-chronic pain drugs with limited CNS-related side effects. In this proposal, we will improve and optimize MrgX1 allosteric agonists and test their analgesic efficacy in mice. Highly selective agonists, and for the purpose of this proposal, allosteric agonists, are needed in order to better understand the respective role of MrgX1 in these studies of chronic pain. We have recently discovered a novel class of allosteric agonists with potency on MrgX1 and selectivity against MrgX2. These selective allosteric agonists offer a unique opportunity to test the hypothesis presented in this proposal. In order to develop first-in-class, potent, selective and CNS penetrant MrgX1 allosteric agonists, we will optimize our lead scaffold such that the tool compound will possess the appropriate properties, a balance of potency, selectivity and DMPK. We will utilize an iterative medicinal chemistry approach which will enable all of the attributes to be evaluated in parallel. Once the tool compound(s) have been determined, we will then test these compounds in the humanized MrgX1 mouse model.
慢性疼痛是世界范围内的一个主要健康和经济问题。因为主要的镇痛药(如阿片类药物)

项目成果

期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Synthesis and Biological Characterization of a Series of 2-Sulfonamidebenzamides as Allosteric Modulators of MrgX1.
作为 MrgX1 变构调节剂的一系列 2-磺酰胺苯甲酰胺的合成和生物学表征。
  • DOI:
    10.1021/acsmedchemlett.2c00100
  • 发表时间:
    2022
  • 期刊:
  • 影响因子:
    4.2
  • 作者:
    Sharma,Swagat;Peng,Qi;Vadukoot,AnishK;Aretz,ChristopherD;Jensen,AaronA;Wallick,AlexanderI;Dong,Xinzhong;Hopkins,CoreyR
  • 通讯作者:
    Hopkins,CoreyR
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Corey R. Hopkins其他文献

Analogues substitues 2-(4-heterocyclylbenzyle)isoindoline-1-un employes comme modulateurs allosteriques positifs du recepteur m1 acetylcholine muscarinique
类似物取代 2-(4-杂环基苯甲基)异吲哚啉-1-un 采用了 m1 乙酰胆碱毒蕈碱受体的变构调节剂
  • DOI:
  • 发表时间:
    2012
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Craig W. Lindsley;P. J. Conn;Michael R. Wood;Corey R. Hopkins;B. J. Melancon;Michael S. Poslusney;Darren W. Engers
  • 通讯作者:
    Darren W. Engers
The backbone constitution drives passive permeability independent of side chains in depsipeptide and peptide macrocycles inspired by ement/em-verticilide
主链结构驱动去酯肽和受 ement/em-verticilide 启发的肽大环中独立于侧链的被动渗透
  • DOI:
    10.1039/d4sc02758b
  • 发表时间:
    2024-09-18
  • 期刊:
  • 影响因子:
    7.400
  • 作者:
    Madelaine P. Thorpe;Abigail N. Smith;Daniel J. Blackwell;Corey R. Hopkins;Bjorn C. Knollmann;Wendell S. Akers;Jeffrey N. Johnston
  • 通讯作者:
    Jeffrey N. Johnston
Potentialisateurs allostériques de mglur4, compositions, et méthodes de traitement d'un dysfonctionnement neurologique
mglur4 的异构潜力、神经功能障碍的成分和方法
  • DOI:
  • 发表时间:
    2010
  • 期刊:
  • 影响因子:
    0
  • 作者:
    P. J. Conn;Craig W. Lindsley;Corey R. Hopkins;Colleen M. Niswender;R. D. Gogliotti
  • 通讯作者:
    R. D. Gogliotti
Potentialisateurs allostériques mglur4, composition et méthodes de traitement de dysfonctionnements neurologiques
mglur4异构潜能、神经功能障碍特征的组成和方法
  • DOI:
  • 发表时间:
    2010
  • 期刊:
  • 影响因子:
    0
  • 作者:
    P. J. Conn;Craig W. Lindsley;Corey R. Hopkins;Charles David Weaver;Colleen M. Niswender;Darren W. Engers;Patrick R. Gentry;Yiu;J. M. Salovich;R. D. Gogliotti
  • 通讯作者:
    R. D. Gogliotti

Corey R. Hopkins的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Corey R. Hopkins', 18)}}的其他基金

Discovery and characterization of selective GIRK1/2 activators and their evaluation in preclinical models of pain
选择性 GIRK1/2 激活剂的发现和表征及其在临床前疼痛模型中的评估
  • 批准号:
    10590728
  • 财政年份:
    2022
  • 资助金额:
    $ 39.25万
  • 项目类别:
Discovery and characterization of selective D4R antagonists and their evaluation in preclinical models of PD-LIDs
选择性 D4R 拮抗剂的发现和表征及其在 PD-LID 临床前模型中的评估
  • 批准号:
    10434146
  • 财政年份:
    2021
  • 资助金额:
    $ 39.25万
  • 项目类别:
Discovery and characterization of selective D4R antagonists and their evaluation in preclinical models of PD-LIDs
选择性 D4R 拮抗剂的发现和表征及其在 PD-LID 临床前模型中的评估
  • 批准号:
    10642849
  • 财政年份:
    2021
  • 资助金额:
    $ 39.25万
  • 项目类别:
Discovery and characterization of selective D4R antagonists and their evaluation in preclinical models of PD-LIDs
选择性 D4R 拮抗剂的发现和表征及其在 PD-LID 临床前模型中的评估
  • 批准号:
    10314276
  • 财政年份:
    2021
  • 资助金额:
    $ 39.25万
  • 项目类别:
Optimization of MrgX1 allosteric agonists as potential therapies for chronic pain
MrgX1 变构激动剂的优化作为慢性疼痛的潜在疗法
  • 批准号:
    9903279
  • 财政年份:
    2017
  • 资助金额:
    $ 39.25万
  • 项目类别:
Optimization of novel inhibitors of TRPC5 as anti-proteinuric therapeutics
新型 TRPC5 抑制剂作为抗蛋白尿疗法的优化
  • 批准号:
    9335339
  • 财政年份:
    2016
  • 资助金额:
    $ 39.25万
  • 项目类别:
Development of an In Vivo, Brain-penetrant GIRK1/2 Potassium Channel Activator
体内脑渗透性 GIRK1/2 钾通道激活剂的开发
  • 批准号:
    8941166
  • 财政年份:
    2015
  • 资助金额:
    $ 39.25万
  • 项目类别:
Development of an In Vivo, Brain-penetrant GIRK1/2 Potassium Channel Activator
体内脑渗透性 GIRK1/2 钾通道激活剂的开发
  • 批准号:
    9090183
  • 财政年份:
    2015
  • 资助金额:
    $ 39.25万
  • 项目类别:
Optimization of novel inhibitors of TRPC5 as anti-proteinuric therapeutics
新型 TRPC5 抑制剂作为抗蛋白尿疗法的优化
  • 批准号:
    8800654
  • 财政年份:
    2014
  • 资助金额:
    $ 39.25万
  • 项目类别:
Optimization of novel inhibitors of TRPC5 as anti-proteinuric therapeutics
新型 TRPC5 抑制剂作为抗蛋白尿疗法的优化
  • 批准号:
    8926413
  • 财政年份:
    2014
  • 资助金额:
    $ 39.25万
  • 项目类别:

相似海外基金

Affective Computing Models: from Facial Expression to Mind-Reading
情感计算模型:从面部表情到读心术
  • 批准号:
    EP/Y03726X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.25万
  • 项目类别:
    Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
  • 批准号:
    2336167
  • 财政年份:
    2024
  • 资助金额:
    $ 39.25万
  • 项目类别:
    Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
  • 批准号:
    2402691
  • 财政年份:
    2024
  • 资助金额:
    $ 39.25万
  • 项目类别:
    Standard Grant
Affective Computing Models: from Facial Expression to Mind-Reading ("ACMod")
情感计算模型:从面部表情到读心术(“ACMod”)
  • 批准号:
    EP/Z000025/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.25万
  • 项目类别:
    Research Grant
Individual differences in affective processing and implications for animal welfare: a reaction norm approach
情感处理的个体差异及其对动物福利的影响:反应规范方法
  • 批准号:
    BB/X014673/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.25万
  • 项目类别:
    Research Grant
Interface: Transplants, Aesthetics and Technology (Previously About Face: The affective and cultural history of face transplants)
界面:移植、美学和技术(之前关于面部:面部移植的情感和文化历史)
  • 批准号:
    MR/Y011627/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.25万
  • 项目类别:
    Fellowship
Tracing the brain mechanisms of affective touch.
追踪情感触摸的大脑机制。
  • 批准号:
    23K19678
  • 财政年份:
    2023
  • 资助金额:
    $ 39.25万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Affective and Immaterial Labour in Latin(x) American Culture
拉丁美洲文化中的情感和非物质劳动
  • 批准号:
    AH/V015834/2
  • 财政年份:
    2023
  • 资助金额:
    $ 39.25万
  • 项目类别:
    Fellowship
Imagination under Racial Capitalism: the Affective Salience of Racialised and Gendered Tropes of 'Black excellence'
种族资本主义下的想象力:“黑人卓越”的种族化和性别化比喻的情感显着性
  • 批准号:
    2889627
  • 财政年份:
    2023
  • 资助金额:
    $ 39.25万
  • 项目类别:
    Studentship
Home/bodies: Exploring the affective experiences of people at home using scenographic practice and ecological thinking
家/身体:利用场景实践和生态思维探索人们在家中的情感体验
  • 批准号:
    2888014
  • 财政年份:
    2023
  • 资助金额:
    $ 39.25万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了